News / Stock

Recordati bets on Japan with the Juxtapid drug. For Alphie the stock can still earn.

Feb 11, 2019 - 15:10 UTC

Recordati has had a positive increase in the last few days: the Italian pharmaceutical company reached its peak on 5th February with a target price of 33.15 EUR, the highest price in the last 6 months. The Italian multinational announced an agreement with the Japanese Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics. The contract provides the exclusive license of sale for the drug Juxtapid in Japan, used for patients with familial hypercholesterolemia. Recordati will have to pay 5 million dollars in the near future and the other 25 million are expected to be given at a later stage. The agreement…

Register to continue reading for free